Third Harmonic Bio Inc.

Third Harmonic Bio — Investor Presentation (June 2025)

38 slides from Third Harmonic Bio's investor presentation, Jun 12, 2025

  1. Slide 1: Focused on advancing the next wave of medicine for inflammatory diseases

    FOCUSED On advancing the next wave of medicine for inflammatory diseases JUNE 2025 ©2025 THIRD HARMONIC BIO Exhibit 99.1

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. Any statements made in this presentation that are not statements of historical fact, inclu

  3. Slide 3: Summary and Next Steps

    Summary and Next Steps Liquidation and Dissolution on-track and sale process of THB335 underway Stockholders approved liquidation and dissolution of the Company Initial distribution currently expected in the range between approximately $5.30 and $5.35 per share of common stock, expected in the third

  4. Slide 4: THRD: Focused on KIT to Treat Mast Cell-Mediated Inflammatory Diseases

    “PIPELINE-IN-A-TARGET” POTENTIAL CLINICAL CANDIDATE: THB335 KIT: A NOVEL, CLINICALLY VALIDATED TARGET LARGE ESTABLISHED MARKETS WITH HIGH UNMET NEED THRD: Focused on KIT to Treat Mast Cell-Mediated Inflammatory Diseases Millions of patients living with severe mast cell-mediated diseases; high residu

  5. Slide 5: High Disease Burden in Chronic Spontaneous Urticaria

    Prevalence: More than 1.5 million patients or 0.5-1% point prevalence; ~70-80% female, mean age ~46 years Disease impact: CSU severely impairs quality of life, causes significant physical discomfort and emotional distress, including anxiety, depression, insomnia and social isolation Limited treatmen

  6. Slide 6: KIT is the Master Regulator of Mast Cell Function and Survival

    KIT is the Master Regulator of Mast Cell Function and Survival Oral small molecule approach to KIT offers multiple potential therapeutic advantages KIT Targeting mast cell vs specific activating pathways or downstream mediators provides broad approach to addressing disease symptoms Emerging clinical

  7. Slide 7: THB335 Product Profile

    THB335: A Next-Generation, Potent, and Highly Selective Wild-Type KIT Inhibitor Low nanomolar KIT potency with excellent kinome selectivity in biochemical and cell-based assays Peripherally restricted biodistribution Structural and metabolic improvements vs THB001 to address DILI risk Favorable nonc

  8. Slide 8: In Vitro Pharmacology Overview

    THB335 In Vitro Pharmacology Overview Potent, selective, reversible KIT kinase inhibitor DiscoverX KinomeSCAN @ 1μM KIT Biochemical Cellular Kinase Target KD (nM) HTRF KIT IC50 (nM) Multiple (nM) KIT 1.5 16.1 5.01 – 7.92 CSF1R 33 56 >30003 – >100002 PDGFRα NT 2710 NT PDGFRβ 34 737 >30004 ABL1 NT NT

  9. Slide 9: Phase 1 Trial Design

    THB335: Phase 1 SAD/MAD/Food Effect in Healthy Volunteers Assess safety and tolerability Characterize pharmacokinetics Measure pharmacodynamic effect by serum tryptase Key Objectives Phase 1 Trial Design Single Ascending Dose (n=40) (fasted unless otherwise specified) Healthy Male/Female, 18-65 yrs

  10. Slide 10: Additional THB335 Phase 1 100mg MAD Cohort

    Additional THB335 Phase 1 100mg MAD Cohort Key changes vs original Phase 1 trial MAD cohorts Utilized a new drug product capsule formulation that is intended for use in future clinical development (Gen 2) vs FIH API in capsule used for original Phase 1 cohorts (Gen 1) Lab draws decreased by ~1/2 to

  11. Slide 11: 100mg MAD Cohort Pharmacokinetics Summary

    THB335 100mg MAD Cohort Pharmacokinetics Summary Consistent PK with 164mg dose level in original MAD cohort of the Phase 1 trial THB335 MAD PK 1 One subject discontinued at day 3 due to unrelated hypertension THB335 Plasma Conc (ng/mL) Time (day) Dose KIT IC90 Coverage Placebo (n=3) N/A Gen 2 100 mg

  12. Slide 12: 100mg MAD Cohort Pharmacodynamics Summary – Serum Tryptase

    THB335 100mg MAD Cohort Pharmacodynamics Summary – Serum Tryptase Consistent serum tryptase reductions with 164mg dose level in original MAD cohort of the Phase 1 trial Dose Serum Tryptase Mean % Reduction at Day 15 Placebo (n=3) -16% Gen 2 100 mg (n=7) -85% Gen 1 164 mg (n=5)1 -84% Placebo 100 mg T

  13. Slide 13: 100mg MAD Cohort Safety Summary

    THB335 100mg MAD Cohort Safety Summary Adverse events reported ≥ 2 subjects 100 mg N=7 Placebo N=3 Pruritus 3 0 Somnolence 3 0 Abdominal distension 2 0 Constipation 2 0 Erythema 2 0 Flatulence 2 0 Muscle spasms 2 0 Pain in extremity 2 0 One moderate AE of neutrophil reduction; known on-target effect

  14. Slide 14: 100mg MAD Cohort Safety: Hemoglobin and ANC

    THB335 100mg MAD Cohort Safety: Hemoglobin and ANC No adverse events related to hemoglobin Expected on-target dose-dependent reductions in ANC; one moderate adverse event Hemoglobin (g/dL) Mean value Study day ULN LLN LLN ULN Neutrophils (absolute) (Thou/uL) Mean value Study day ULN LLN Placebo 100

  15. Slide 15: Original Phase 1 MAD Cohorts Previously Presented Data

    Original Phase 1 MAD Cohorts Previously Presented Data

  16. Slide 16: MAD Pharmacokinetics Summary

    THB335 MAD Pharmacokinetics Summary T1/2 ~40 hours Mild positive food effect 41% variability coefficient THB335 MAD PK 21 mg 41 mg 82 mg 164 mg THB335 plasma concentration (ng/mL) Time (days) IC90 IC50 Dose KIT IC90 Coverage Placebo (n=8) na 21 mg (n=6) ~0.5x 41 mg (n=6) ~2x 82 mg (n=6) ~4.5x 164 mg

  17. Slide 17: MAD Pharmacodynamics Summary – Serum Tryptase

    THB335 MAD Pharmacodynamics Summary – Serum Tryptase Dose Serum Tryptase Mean % Reduction at Day 15 Placebo (n=8) 0.8% 21 mg (n=6) -13% 41 mg (n=6) -50% 82 mg (n=6) -59% 164 mg (n=5)1 -84% Tryptase values below lower limit of quantification (LLOQ; 1 ng/mL) were imputed at 0 ng/mL 1 One subject disco

  18. Slide 18: MAD Pharmacodynamics Summary – Stem Cell Factor

    THB335 MAD Pharmacodynamics Summary – Stem Cell Factor THB335 MAD Stem Cell Factor Dose Stem Cell Factor Mean % Increase at Day 16 Placebo (n=8) 0.4% 21 mg (n=6) 9% 41 mg (n=6) 23% 82 mg (n=6) 43% 164 mg (n=5)1 56% 1 One subject discontinued at day 3 due to unrelated hypertension Mean/SD Percent Cha

  19. Slide 19: MAD Safety Summary

    THB335 MAD Safety Summary Adverse events reported ≥ 2 subjects AE TERM Dose 21 mg 41 mg 82 mg 164 mg Placebo Hair Depigmentation 0 0 3 4 0 Low Hemoglobin 0 0 2 5 0 Decreased WBC 0 1 1 2 0 Low ANC 0 1 0 2 0 Elevated Liver Enzymes 0 0 0 1 2 Headache 0 1 0 0 1 Contact Dermatitis due to EKG leads 1 0 0

  20. Slide 20: MAD Safety: ALT/AST Elevations

    THB335 MAD Safety: ALT/AST Elevations Mild/moderate, asymptomatic and transient transaminase elevations in 3 subjects (2 placebo, 1 active) Numeric result Study day ALT (U/L) AST (U/L) Placebo (21 mg cohort) Placebo (164 mg cohort) Active (164 mg cohort) High In range ALT >500 U/L is international s

  21. Slide 21: MAD Safety: Neutrophils (ANC)

    Expected on-target dose-dependent reductions in ANC All values normalized by follow-up day 38 THB335 MAD Safety: Neutrophils (ANC) Neutrophils (absolute) ANC (109/L) 21 mg 41 mg 82 mg 164 mg Placebo ULN ULN LLN Visit day Mean value

  22. Slide 22: MAD Safety: Hemoglobin

    Hemoglobin (g/dL) THB335 MAD Safety: Hemoglobin 21 mg 41 mg 82 mg 164 mg Placebo Evidence of phlebotomy effect in decreased hemoglobin in placebo subjects Lower baseline values in 164 mg cohorts may contribute to AE severity ULN LLN LLN ULN Mean value Visit day

  23. Slide 23: MAD Hematology Safety Summary

    THB335 MAD Hematology Safety Summary AE TERM Severity Dose 21 mg 41 mg 82 mg 164 mg Low hemoglobin Mild 0 0 0 0 Moderate 0 0 2 2 Severe 0 0 0 3 Low ANC Mild 0 0 0 0 Moderate 0 1 0 1 Severe 0 0 0 1 Low WBC Mild 0 1 1 1 Moderate 0 0 0 1 Severe 0 0 0 0 Hemoglobin AEs graded utilizing FDA preventative v

  24. Slide 24: MAD Safety: Hemoglobin

    THB335 MAD Safety: Hemoglobin Mean Hemoglobin (SD) (g/dL) Day 1 Day 14 Day 22 Day 29/EOS Placebo (n=8) 12.9 (1.22) 12.8 (1.11) 12.2 (1.18) 12.6 (0.93) 21 mg (n=6) 12.8 (0.56) 12.4 (0.55) 12.2 (0.53) 12.3 (0.72) 41 mg (n=6) 14.2 (0.95) 14.0 (1.35) 13.1 (1.19) 13.4 (1.01) 82 mg (n=6) 14.0 (0.68) 12.7

  25. Slide 25: Phase 1 Clinical Trial Results Summary

    THB335 Phase 1 Clinical Trial Results Summary Once daily dosing with dose-dependent increases in exposure exceeded the KIT IC90 at doses > 41mg Sustained, dose-dependent decreases in serum tryptase Most recent clinical data demonstrates encouraging safety profile with minimal on-target adverse event

  26. Slide 26: "Pipeline-in-a-Target" Potential with KIT Inhibition

    “Pipeline-in-a-Target” Potential with KIT Inhibition In addition to CSU, opportunity to pursue additional mast-cell mediated inflammatory disorders Meaningful opportunity in severe asthma, where mast cells play a central role in pathophysiology and clear need exists for new oral therapies Other comp

  27. Slide 27: Summary and Next Steps

    Summary and Next Steps Plan of Liquidation and Dissolution on-track and sale process of THB335 underway Stockholders approved liquidation and dissolution of the Company Initial distribution currently expected in the range between approximately $5.30 and $5.35 per share of common stock, expected in t

  28. Slide 28: Appendix

    APPENDIX

  29. Slide 29: Original MAD Cohorts Baseline Characteristics

    THB335 Original MAD Cohorts Baseline Characteristics Variable Dose 21 mg N=6 41 mg N=6 82 mg N=6 164 mg N=6 Placebo N=8 Sex, n (%) Female 6 (100%) 3 (50%) 6 (100%) 6 (100%) 8 (100%) Male 0 (0%) 3 (50%) 0 (0%) 0 (0%) 0 (0%) Age (years) Median 55.5 51.5 58.0 56.0 53.0 Race, n (%) White 6 (100.0%) 5 (8

  30. Slide 30: 100mg MAD Cohort Baseline Characteristics

    THB335 100mg MAD Cohort Baseline Characteristics Variable 100 mg N=7 Placebo N=3 Sex, n (%) Female 7 (100%) 2 (66.7%) Male 0 (0.0%) 1 (33.3%) Age (years) Median 56.0 53.0 Race, n (%) White 6 (85.7%) 3 (100.0%) Black or African American 1 (14.3%) 0 (0.0%) Ethnicity, n (%) Hispanic or Latino 5 (71.4%)

  31. Slide 31: First-Generation THB001 Phase 1b CINDU Study Overview

    First-Generation THB001 Phase 1b CINDU1 Study Overview Discontinued dose escalation study designed to interrogate potential for therapeutic index optimization Design and Objectives 3 doses (1:1:1) of THB001 (total N=30) for 12 weeks Pharmacokinetics and serum tryptase levels Mean reduction in critic

  32. Slide 32: Early Clinical Proof-Of-Concept Demonstrated With THB001

    Early Clinical Proof-Of-Concept Demonstrated With THB001 Discontinued cold inducible urticaria study results CLINICAL RESPONSES GENERATED AT LOWEST PLANNED DOSE Rapid tryptase reduction: -83% mean change from baseline by week 1 Strong correlation between serum tryptase reduction and clinical respons

  33. Slide 33: THB001 Phase 1b CINDU Study Efficacy Summary

    First-Generation THB001 Phase 1b CINDU Study Efficacy Summary 4 of 5 subjects reached partial (n=2) or complete (n=2) responses at lowest planned dose of 200mg BID Rapid tryptase reduction: -83% mean change from baseline by week 1 Strong correlation between serum tryptase reduction and clinical resp

  34. Slide 34: THB001 Phase 1b CINDU Study Safety Summary

    11 1000 First-Generation THB001 Phase 1b CINDU Study Safety Summary No serious or severe AEs Two moderate AEs of transaminitis which resolved at weeks 17 and 25 of follow-up All other AEs were mild Overall profile consistent with on-target effects of KIT inhibition observed in the Phase 1a study (e.

  35. Slide 35: THB001 Showed Evidence of Reactive Metabolite Formation

    THB001 Showed Evidence of Reactive Metabolite Formation Mechanistic studies provide potential basis for observed transaminitis [14C] THB001 Covalent Protein Adduct Formation in Human Liver Microsomes is reduced in the presence of gSH or CYP inhibition 1 Published literature cut-off: Evans D.C. et al

  36. Slide 36: THB335 is Metabolically Distinct from THB001

    THB335 is Metabolically Distinct from THB001 Next-generation structural modifications functionally block the site of reactive metabolite formation Diol formed via a reactive epoxide identified as major metabolite of THB001 GSH adduct formation associated with detoxification pathways Next-generation

  37. Slide 37: Next-Gen is Phenotypically Distinct from THB001 in Human Hepatocyte Culture

    1Gene sets derived from 2Molecular Signatures Database (MSigDB), 3Insphero and 4Toxicogenomics. 5Kang, W., et al.. Toxicol Sci, 2020. 177(1): p. 121-139. 6THB732 is a next-generation tool compound with high structural similarity to THB335 Next-Gen is Phenotypically Distinct from THB001 in Human Hepa

  38. Slide 38: Third Harmonic Bio

    Third Harmonic Bio

Third Harmonic Bio — Investor Presentation (June 2025) on 6ix